This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \<18 years (Cohort A), children aged 2 to \<12 years (Cohort B), and infants aged 1 to \<24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Occurrence of Adverse Events (AEs) following administration of Regadenoson
Timeframe: 70 hours after Regadenoson administration
Changes in physical examinations following administration of Regadenoson
Timeframe: Baseline and 2 hours after Regadenoson administration
Changes in physical examinations following administration of Regadenoson
Timeframe: Baseline and 2 hours after Regadenoson administration
Changes in oxygen saturation following administration of Regadenoson
Timeframe: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration
Changes in blood pressure in mmHg following administration of Regadenoson
Timeframe: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration
Changes in heart rate as bpm following administration of Regadenoson
Timeframe: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration
Changes in body temperature (as degree C) following administration of Regadenoson
Timeframe: Baseline and 2 hours after Regadenoson administration
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of Regadenoson
Timeframe: Baseline, 1 and 2 hours after Regadenoson administration
Changes in serum chemistry following administration of regadenoson
Timeframe: Baseline and 2 hours after Regadenoson administration
Time changes of regadenoson blood concentrations (ng/mL) with a single, body-weight adjusted i.v. dose in 3 paediatric populations: adolescents 12 to <18 years,children 2 to <12 years, and infants 1 to <24 months, and who weigh at least 3kg.
Timeframe: 1, 3, 5, 10, and 20 minutes and 1 and 2 hours post Regadenoson administration